Rifampicin polylactic acid microspheres for lung targeting.

Area of Science:

• Pharmacology
• Materials Science
• Biomedical Engineering

Background:

• Lung targeting offers potential for localized treatment of respiratory diseases.
• Microsphere-based drug delivery systems can improve therapeutic efficacy and reduce systemic side effects.
• Rifampicin is a key antibiotic used in treating tuberculosis, a major lung infection.

Purpose of the Study:

• To prepare and characterize rifampicin-loaded polylactic acid microspheres for enhanced lung targeting.
• To evaluate the in vitro drug release profile and in vivo biodistribution of the microspheres.

Main Methods:

• Modified emulsion-solvent diffusion method was employed for microsphere preparation.
• Microsphere characteristics including morphology, particle size distribution, and drug content were analyzed.
• In vitro drug release studies were conducted.
• In vivo experiments in rabbits were performed to assess lung accumulation.

Main Results:

• Rifampicin polylactic acid microspheres were successfully prepared, exhibiting free-flowing, spherical morphology with a regular surface.
• Characterization confirmed suitable particle size distribution and drug content for pulmonary administration.
• In vitro release studies demonstrated controlled drug release kinetics.
• In vivo studies in rabbits revealed remarkable accumulation of the microspheres within the lung tissue.

Conclusions:

• The developed rifampicin polylactic acid microspheres are suitable for lung targeting.
• The modified emulsion-solvent diffusion method is effective for producing lung-targeted microspheres.
• These microspheres show promise for improved pulmonary drug delivery of rifampicin.